Avalon Pharma Co. intrinsic value and dividend analysis using DCF, P/B, PEG and PSG models. Includes dividend yield, payout ratio, and dividend sustainability assessment. Sector: PharmaBiotech & Life Science. Listed on Saudi Exchange Tadawul.
Middle East Pharmaceutical Industries Company, operating as Avalon Pharma, researches, develops, and manufactures generic medicines across dermatological, respiratory, cardiovascular, and central nervous system categories. It markets its products in Saudi Arabia and abroad through Private, Public, and Export segments. Formerly Middle East Chemical Products Factory Company, it was incorporated in 1998 and is headquartered in Riyadh.
TASIV estimates this company's intrinsic value using a DCF (Discounted Cash Flow) model. As of TASIV's most recent data refresh, the estimated intrinsic value is SAR 41.57 compared to a market price of SAR 66.60 (Trading significantly above DCF model value). This is an analytical estimate, not investment advice.
Revenue increased by about 36% over the three-year period, while net income grew faster, at about 47%, indicating profitability increased faster than sales. Operating cash flow, by contrast, ended about 4% lower than where it started, falling sharply in the second year before largely recovering in the third. Overall, revenue and net income both grew, while operating cash flow fluctuated but ended close to its starting level.
Dividend per share fluctuated over the 3-year recorded period, ranging between SAR 0.75 and SAR 2.35, and ended at SAR 2.12 versus SAR 0.75 at the start. Payments have been made on an Annual basis throughout this period. Overall, the company's per-share dividend has varied year to year without a consistent direction. Current dividend yield is approximately 3.18%, with a payout ratio of approximately 76.49%.
TASIV's Competitive Advantage assessment for this company is High (95/100), based on profitability, predictability, financial strength, and growth resilience.
Based on TASIV's DCF (Discounted Cash Flow) model, the estimated intrinsic value of Avalon Pharma Co. is approximately SAR 41.57, compared to a current market price of SAR 66.60. This is an analytical estimate based on the company's financial data, not investment advice or a recommendation to buy or sell.
According to TASIV's model, Avalon Pharma Co. is currently "Trading significantly above DCF model value".
Avalon Pharma Co.'s dividend yield is approximately 3.18%, with a payout ratio of approximately 76.49%, based on TASIV's most recent verified data.
Loading 4016...